Methods
This study was performed as part of a prospective multicenter cohort study to assess medical outcomes in elderly patients with acute symptomatic venous thromboembolism from nine Swiss university and non-university hospitals (09/2009-12/2013). 6 A detailed description of the study methods has been published previously. 6 Briefly, consenting consecutive patients aged ≥65 years with objectively In all patients a blood sample was taken 12 months after index venous thromboembolism. Samples were immediately centrifuged, frozen, and stored at -80°C and sent for analyses to a central study labo ratory. D-dimer was determined by ELISA (VIDAS, bioMérieux). Normal D-dimer was defined according to the cutoff value recommended by the manufacturer (normal <500 ng/ml). In addition, given that all patients were aged ≥65 years in our cohort, we also calculated age-adjusted cutoff values (patient's age multiplied by 10) to take into account higher D-dimer levels in the elderly. 7 The outcome was the recurrence of symptomatic, objectively confirmed venous thromboembolism after D-dimer measurement, defined as symptomatic new deep vein thrombosis or pulmonary embolism based on predefined imaging criteria or autopsy, as previously described. 6 Three blinded, independent experts adjudicated all recurrences.
We compared baseline characteristics between patients with normal and abnormal D-dimer values using the chi-squared test and the non-parametric
Wilcoxon rank-sum test as appropriate. We examined associations between logtransformed and dichotomized D-dimer values and the time to a first venous thromboembolism recurrence using competing risk regression according to Fine and Gray, 8 accounting for non-pulmonary-embolism-related death as a competing event.
Adjustment was done for age, sex, and overt pulmonary embolism. We estimated M A N U S C R I P T A C C E P T E D ng/ml and the median D-dimer value of all patients with a value of ≥500 ng/ml. We considered P values <0.05 to be statistically significant. All analyses were done using Stata 13 (Stata Corporation, College Station, Texas).
Results
Of the 225 patients with unprovoked venous thromboembolism who successfully completed a 3 to 12-month course of anticoagulation and survived the first 12 months initially enrolled in our cohort, we excluded 36 without D-dimer measurement, and 32 who withdrew consent or denied data use within the first year.
Our final study sample comprised 157 patients with acute unprovoked venous thromboembolism. appeared to have no effect on prediction of venous thromboembolism recurrence in previous studies. 9 Finally, our study used a specific D-dimer test (ELISA VIDAS) and therefore our results may not be necessarily applicable to other D-dimer tests.
M A N U S C R I P T A C C E P T E D
In conclusion, D-dimer testing alone may not be useful in identifying elderly patients with unprovoked venous thromboembolism who are at low risk of recurrent venous thromboembolism and in whom anticoagulants may be safely stopped. 
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Clinical significance
• D-dimer levels were not significantly associated with recurrent venous thromboembolism in the elderly with unprovoked venous thromboembolism.
• The negative likelihood ratio (0.34) and the discriminative power (0.66) of post-anticoagulation D-dimer for predicting recurrence in elderly patients with unprovoked venous thromboembolism were only moderate.
• Post-anticoagulation D-dimer testing alone was not useful in identifying elderly patients with unprovoked venous thromboembolism who are at low risk of recurrence.
